PRAISE-U moves prostate cancer screening from policy statement to working protocol
Prostate cancer remains one of Europe’s heaviest cancer burdens, with about 335,000 new cases and more than 100,000 deaths each year across the EU. One in 11 men is expected to receive the diagnosis by age 74, a scale that forces screening policy to confront a difficult balance: finding clinically significant disease early while avoiding the cascade of unnecessary testing, biopsy, and treatment that follows detection of low-risk tumors.
Prostate cancer screening is no longer being discussed as a simple PSA yes-or-no question. The current European debate is centered on how to separate men who need closer evaluation from those who can safely avoid invasive workups, and that shift is the foundation of PRAISE-U.
The EU4Health-funded project was built to turn a 2022 European Council recommendation into a practical service model. For the first time, prostate cancer was named alongside lung and gastric cancer as suitable for organized, population-based screening, with member states invited to pilot and study stepwise implementation before national rollouts. In plain clinical terms, the question changed from whether screening might help to how a real screening program should work inside different health systems.
Why opportunistic PSA testing has not delivered population benefit
For years, many European men who wanted a PSA test simply asked a general practitioner, with little standardization around age thresholds, repeat testing, risk assessment, or follow-up. This opportunistic model reaches a self-selected group of men and does not operate under a fixed protocol. It is common, familiar, and inefficient.
The problem is not only inconsistent quality. Unregulated PSA testing has been linked to large-scale overdiagnosis, with wide variation in incidence across Europe that is far out of proportion to mortality differences. The article points to up to a 20-fold variation in prostate cancer incidence between countries against only a five-fold variation in mortality, a pattern more consistent with testing intensity than with true biological differences in disease burden.
A single elevated PSA value can trigger a chain of events that ends in biopsy, imaging, and treatment for cancers that would never have threatened the patient’s life. In that sense, opportunistic testing can convert a biomarker into a driver of harm when it is detached from structured risk stratification.
PRAISE-U adds MRI and risk calculators before biopsy
PRAISE-U, or Prostate cancer Awareness and Initiative for Screening in the European Union, is evaluating a risk-stratified population-based screening approach in Ireland, Lithuania, Poland, and two regions in Spain, Galicia and Manresa. Men aged 50 to 69 in the catchment areas are invited to participate. Those who consent undergo PSA testing, and elevated results then move into a staged diagnostic pathway that includes the validated Rotterdam Prostate Cancer Risk Calculator and MRI before any biopsy decision.
This double risk-stratification design is the project’s clinical center of gravity. PSA alone has limited specificity, especially in a disease where indolent lesions are common. Risk calculators and MRI are meant to improve triage, raising the chance that biopsy is reserved for men with a meaningful probability of clinically significant cancer. Early pilot data indicate the algorithm is feasible and reduces unnecessary MRI studies and biopsies.
That reduction matters at the bedside. Fewer biopsies mean fewer infections, bleeding events, anxiety-provoking false positives, and treatment decisions based on disease that may never have required intervention. Fewer unneeded MRI scans also lower pressure on imaging services that are already unevenly distributed across Europe.
The same screening protocol has to work in very different systems
Running the pilots in five sites was not an administrative detail. It was a deliberate test of portability. Ireland, Lithuania, Poland, Galicia, and Manresa do not share the same degree of health-system organization, MRI access, radiologist experience, or referral infrastructure. A screening pathway that depends on one country’s local strengths can fail when exported to another setting without adaptation.
To address that, PRAISE-U developed a shared set of key performance indicators so each site can be measured in the same way. Interval-cancer rates, biopsy rates, and psychosocial impact are among the outcomes being tracked. If interval cancers rise, investigators can examine whether the protocol is missing significant disease, whether screening intervals are too long, or whether the risk-stratification process needs revision.
The project also completed an MRI capacity assessment across all five sites, and the variation was substantial. Radiologist expertise and referral pathways differed across countries, which means imaging quality assurance may determine success as much as the PSA threshold itself. A screening algorithm can look elegant on paper and still perform poorly if the imaging backbone is uneven.
What clinicians should expect as the pilots close
PRAISE-U has run from April 2023 through September 2026, with a full evaluation due to the European Commission by the end of that period. A follow-on effort, PRAISE-U Plus, is planned to extend the work from proof-of-concept implementation toward national scale-up. The European Association of Urology described the program in mid-2026 as a turning point in Europe’s approach to early detection of prostate cancer.
For clinicians, the practical message is immediate. A PSA test ordered because a man asks for one is not the same as enrollment in a structured screening program. Opportunistic testing remains vulnerable to overdiagnosis, inconsistent follow-up, and treatment decisions detached from a protocol. A formal program, by contrast, is built around invitation, risk stratification, follow-up, and performance monitoring.
PSA testing without a protocol is not screening in the population-health sense.
Where PRAISE-U-informed programs exist or are being piloted, referral into the organized pathway is likely to be more appropriate than ad hoc testing, because the program is designed to reduce unnecessary biopsies and overtreatment while preserving early detection of significant disease. It also offers a route to more equitable access, especially in systems where opportunistic testing has favored men who already know to ask and know how to navigate care.
The larger policy implication is straightforward. Europe is moving away from a “test on request” model and toward organized early detection, but the durability of that shift will depend on whether the pilot data hold up when scaled into national practice. The remaining questions are operational rather than abstract: how much MRI capacity is enough, which PSA thresholds should trigger the next step, and how closely different health systems can reproduce the pilot pathway without diluting its diagnostic performance.